Dr. McKenzie on Navigating the Landscape of Biomarker Testing in NSCLC
Andrew McKenzie, PhD, discusses the variety of molecular testing modalities in patients with metastatic non–small cell lung cancer.
Biomarker Testing Standards-of-Care in Breast and Lung Cancer
The panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.
Monitoring Patients on First-Line Treatment for Metastatic Breast Cancer
Ellen Ball, ANP-FNP, reviews how patients are monitored for treatment response and toxicities during first-line treatment.
Targeted Therapy in Metastatic Breast Cancer for Patients with BRCA Mutations
Key opinion leaders explain how early they introduce targeted therapy in mutated breast cancer.
Further Molecular Testing in Early-Stage Metastatic Breast Cancer
Gregory Vidal, MD, PhD, discusses the potential use of further molecular testing in early-stage first-line breast cancer.
Biomarker-Influenced Treatment Approaches for Patients with Metastatic Lung Cancer
Martin Dietrich, MD, PhD, explains the rationale for the chosen treatment approach in the presented clinical scenario of metastatic lung cancer.
Clinical Scenario: A 74-Year-Old Man with Lung Cancer
A panel of experts discusses the clinical scenario of a 74-year-old man with metastatic lung cancer and the best genetic testing approach.
Discussing Biomarker Testing with Patients
Ellen Ball, ANP-FNP, provides a look at the conversations she has with patients when discussing their options for genetic testing in breast cancer.
Use of Liquid Biopsies in Breast Cancer
Drs McKenzie and Vidal debate the use of liquid biopsies in breast cancer.
Challenges of Biomarker Testing in Breast Cancer
Dr Gregory Vidal describes the approaches for biomarker testing in breast cancer and the challenges clinicians face.
Biomarker Testing Interpretation in Breast and Lung Cancer
Andrew McKenzie, PhD, details how to interpret the results of biomarker testing in breast cancer and lung cancer.
Choosing a Molecular Testing Panel for Solid Tumors
Dr Andrew McKenzie explains how to choose the appropriate molecular testing for a patient.
Currently Targetable Mutations in Lung and Breast Cancer
Drs Dietrich and Vidal discuss the currently known targetable actionable mutations in breast cancer and lung cancer.
Clinical Scenario: A 44-Year-Woman with Metastatic Breast Cancer
Dr Martin Dietrich presents a second clinical scenario of a 44-year-old woman with metastatic, highly-aggressive breast cancer.
PD-L1 Expression and IO Therapy in Lung and Breast Cancer
A conversation on PD-L1 biomarker expression in lung cancer, and how it influences treatment with immunotherapy and chemotherapy.
Using Molecular Testing to Guide Treatment Decisions
Gregory Vidal, MD, PhD, highlights the benefits and drawbacks of the available biomarker testing options and how the results guide treatment decision-making.
Available Molecular Tests for Solid Tumors
Andrew McKenzie, PhD, provides an overview of the various forms of molecular testing available for identifying actionable alterations in breast and lung cancer.
Dr. McKenzie on the Rationale for Concurrent Tissue and Liquid Biopsies in Lung Cancer
Andrew McKenzie, PhD, discusses the rationale to utilize concurrent tissue- and liquid-based biopsies in lung cancer.
Black Women With HR+ Breast Cancer Have Worse Outcomes, Despite Similar Recurrence Scores
Benefit of Adjuvant Abemaciclib Increases at 4-Year monarchE Landmark Analysis for Patients With HR+/HER2– High-Risk Early Breast Cancer
Everolimus Plus Adjuvant Endocrine Therapy Fails to Improve iDFS, OS in HR+/HER2- Breast Cancer
Frontline Ribociclib Plus Endocrine Therapy Provides PFS Benefit in Pre/Perimenopausal HR+/HER2- Advanced Breast Cancer
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.